Group 1 - The core point of the article is that Heptagon Pharmaceuticals-B (02142) has successfully completed a placement of shares, fulfilling all conditions outlined in the placement agreement [1] - The placement involved the successful allocation of 45.022 million shares at a price of HKD 11.50 per share to no fewer than six subscribers [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告或其任何文本概不得直接或間接在美國，或在發放或派發本公告屬違法的任何其他司法 權區內發放或派發。 本公告並不構成在美國購買或認購證券的任何要約或招攬，亦不構成其任何一部分。本公告提 及的證券並無且將不會根據《1933年美國證券法》（「美國證券法」）登記，且不得在美國提呈發 售或出售，惟根據美國證券法的規定進行登記，或適用豁免登記，或進行毋須遵守有關登記規 定的交易則除外。本公司無意按照美國證券法於美國登記本公告所述任何證券，亦無意於美國 公開發售證券。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 完成根據一般授權配售新股 獨家整體協調人及獨家配售代理 ݷ 據董事作出一切合理查詢後所深知、盡悉及確信，承配人及彼等各自的最終實益 擁有人均為屬獨立於本公司及其 ...

Group 1: Market Overview - The Hang Seng Index rose by 0.62%, while the Hang Seng Tech Index increased by 0.82%, with a total turnover of HKD 124.6 billion in the morning session [1] - The Hang Seng Biotechnology Index surged by 3.1%, driven by optimism in the innovative drug sector ahead of the 2025 World Lung Cancer Conference, indicating potential for valuation recovery [1] Group 2: Company Performances - Three-Six Pharmaceutical (01530) saw a significant increase of 9.6% [1] - Hengrui Medicine-B (02142) rose by 5.82% [1] - Hutchison China MediTech (00013) increased by 6% [1] - United Laboratories (03933) gained 5% [1] - WuXi Biologics (02269) rose by 4.17% [1] Group 3: Other Notable Stocks - Chow Tai Fook (06168) surged over 13% as the gold consumption market enters a peak season, with expectations of inclusion in the Hong Kong Stock Connect [2] - FunPlus (09890) increased by over 5% after completing a name change and upgrading its overseas brand integration, with a higher proportion of overseas revenue in the first half [2] - Lehua Entertainment (02306) rose by 16%, with a nearly 90% year-on-year increase in interim profit attributable to shareholders, expanding monetization channels for its trendy IP [3] - UBTECH Robotics (09880) increased by 3%, with humanoid robot orders reaching CNY 400 million and securing a USD 1 billion strategic investment from a Middle Eastern fund [4] - Mobi Development (01860) surged over 12%, hitting a historical high with a cumulative increase of over 110% this year [5] - Goldwind Technology (02208) rose over 10%, reaching a new high as the wind power sector experiences accelerated growth, leading the industry in gross margin improvement [5] - Zhongshen Jianye (02503) experienced a significant drop, falling over 74% to a historical low, with a loss of CNY 11.81 million in the first half [5]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant upward trend, with multiple companies showing substantial stock price increases ahead of the 2025 World Lung Cancer Conference [1] - Notable stock price increases include: 9.55% for 3SBio, 6.25% for Hengrui Medicine, and 5.16% for WuXi Biologics, indicating strong market interest [1] - The upcoming conference in Barcelona is expected to provide new development opportunities and market attention for innovative drug companies through the release of significant new products [1] Group 2 - In the first seven months of the year, China's innovative drug companies have seen a normalization in business development (BD) overseas, with license out amounts nearing $80 billion, a year-on-year increase of over 160% [2] - Analysts suggest that the essence of China's innovative drug overseas expansion is to replace certain ecological niches of foreign biotech companies, potentially leading to new breakthroughs in the global innovative drug industry [2] - The deep participation of Chinese innovative drugs in the global supply chain is expected to benefit significantly from the global innovation cycle [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 FF301 第 1 頁 ...

Core Viewpoint - The company announced the granting of stock options and share awards to eligible participants, which is part of its stock option plan and share award plan adopted by shareholders in November 2020 [1] Group 1 - The company granted a total of 843,000 stock options [1] - The company awarded a total of 3,282,000 shares [1] - The grants are subject to acceptance by the recipients to take effect [1]

Core Viewpoint - The company, HAPO Pharmaceutical-B (02142), announced the granting of stock options and share awards to eligible participants, which is part of the stock option plan and share award plan adopted by shareholders in November 2020 [1] Summary by Relevant Sections - Stock Options Granted: The company granted a total of 843,000 stock options to eligible participants [1] - Share Awards Granted: The company also awarded a total of 3,282,000 shares as part of the incentive plans [1] - Effective Date: The grants will take effect upon acceptance by the grantees [1]

Group 1 - The company, He Bo Pharmaceutical-B (02142.HK), announced the grant of 843,000 stock options and a total of 3.282 million shares as rewards to qualified participants, pending acceptance by the grantees [1]

和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 授出購股權及授出股份獎勵 本公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」） 第17.06A條刊發。 和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會（「董 事會」）謹此宣佈，於2025年9月3日，根據本公司股東（「股東」）於2020年11月23 日分別採納的購股權計劃（「購股權計劃」）及股份獎勵計劃（「股份獎勵計劃」），本 公司向合資格參與者授出購股權（「購股權」）及股份獎勵（「獎勵」），惟須待承授人 接納後生效。 授出購股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 授出購股權（「授出購股權」）的詳情如下： 股份於授出日期的市價： 每股股份16.08港元 1 授出日期： 2025年9月3日 所授出購股權數目： 843,000份 承授人數目： 3名本集團非關連僱員（不包括 ...

Core Viewpoint - The article highlights the significant increase in the stock price of Heptagon Pharmaceuticals, driven by substantial investment from GIC, a Singapore sovereign wealth fund, which has raised interest in the innovative drug sector in Hong Kong [2][3]. Group 1: Stock Performance - Heptagon Pharmaceuticals' stock rose by 9.16% on September 3, 2023, with a year-to-date increase of approximately 712% [3]. - The stock closed at 16.08 HKD, with a trading volume of 13.68 million shares and a market capitalization of approximately 13.29 billion HKD [4]. Group 2: GIC Investment - On August 29, 2023, GIC purchased 40.22 million shares of Heptagon Pharmaceuticals at an average price of 12.7133 HKD per share, totaling around 511 million HKD [6]. - Following this investment, GIC holds a 6.37% stake, making it the second-largest institutional shareholder, while AstraZeneca remains the largest with a 9.03% stake [8]. Group 3: AstraZeneca's Involvement - AstraZeneca invested in Heptagon Pharmaceuticals at a 40% premium, becoming the largest institutional shareholder with approximately 76.27 million shares [7][10]. - The investment agreement allows AstraZeneca to have licensing options on two preclinical immunology projects developed by Heptagon Pharmaceuticals [12]. Group 4: Financial Performance - Heptagon Pharmaceuticals reported a total revenue of approximately 725 million RMB (about 101 million USD) for the first half of 2025, marking a 327% year-on-year increase [12]. - The net profit for the same period was approximately 523 million RMB (about 73 million USD), reflecting a 51-fold increase compared to the previous year [12]. - The company's cash reserves reached approximately 2.29 billion RMB (about 320 million USD), a 92% increase from the end of the previous year [12].